歡迎光臨源葉生物,登錄 | 注冊(cè) |
當(dāng)前位置: 首頁 > 小分子抑制劑 > Microbiology/Virology > GSK2330672

瀏覽歷史

S82917

GSK2330672

源葉(MedMol) 99%
  • 英文名:
  • GSK2330672
  • 別名:
  • Pentanedioic acid, 3-((((3R,5R)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,4-benzothiazepin-8-yl)methyl)amino)-; 3-[[(3R,5R)-3-butyl-3-ethyl-7-methoxy-1,1-dioxo-5-phenyl-4,5-d
  • CAS號(hào):
  • 1345982-69-5
  • 分子式:
  • C28H38N2O7S
  • 分子量:
  • 546.6755
  • 核磁/質(zhì)譜:
品牌貨號(hào)產(chǎn)品規(guī)格價(jià)格(RMB) 庫存(上海) 北京 武漢 南京 數(shù)量計(jì)量單位 加入購物車...
源葉(MedMol) S82917-1mg 99% ¥800.00元 5 - - - EA 加入購物車
源葉(MedMol) S82917-5mg 99% ¥2240.00元 6 - - - EA 加入購物車
源葉(MedMol) S82917-10mg 99% ¥3600.00元 5 - - - EA 加入購物車
源葉(MedMol) S82917-50mg 99% ¥10400.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購物車
源葉(MedMol) S82917-100mg 99% ¥14400.00元 預(yù)計(jì)交期:2-3天 - - - EA 加入購物車
大包裝詢價(jià)

提交您的電話號(hào)碼并同意《個(gè)人信息授權(quán)與保護(hù)申明》,到貨后將短信提示。
提交

產(chǎn)品介紹

參考文獻(xiàn)

質(zhì)檢證書(COA)

摩爾濃度計(jì)算器

相關(guān)產(chǎn)品

  • 提示:詳情請(qǐng)下載說明書。
  • 產(chǎn)品描述: Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC50 of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment
  • 靶點(diǎn): IC50: 42 nM (Apical sodium-dependent bile acid transporter (ASBT));HBV
  • 體外研究:
    The zwitterionic, nonhygroscopic, crystalline salt form of Linerixibat (Compound 56) shows good aqueous solubility at pH 7.4 (>7 mg/mL), excellent thermal stability, and did not generate reactive or humanspecific metabolite, characteristics
  • 體內(nèi)研究:
    Linerixibat (GSK2330672; 0.05-10 mg/kg; oral gavage; twice daily; for 14 days; male ZDF rat) treatment lowers glucose in an animal model of type 2 diabetes. Animal Model: Male Zucker Diabetic Fatty (ZDF) rat Dosage: 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg Administration: Oral gavage; twice daily; for 14 days Result: Led to a 1.30-1.64% reduction in hemoglobin A1c (HbA1c), a greater than 50% reduction in nonfasted plasma glucose to below 200 mg/dL, and statistically significant higher plasma insulin.
  • 參考文獻(xiàn):
    1. Wu Y, et al. Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114. 2. Wang Y, et al. HNF4α Regulates CSAD to Couple Hepatic Taurine Production to Bile Acid Synthesis in Mice. Gene Expr. 2018 Aug 22;18(3):187-196. 3. Linerixibat (GSK2330672) granted Orphan Status. September 24, 2019.
  • 溶解性: Soluble  in  DMSO
  • 保存條件: -20℃
  • 配置溶液濃度參考:
    1mg 5mg 10mg
    1 mM 1.829 ml 9.146 ml 18.292 ml
    5 mM 0.366 ml 1.829 ml 3.658 ml
    10 mM 0.183 ml 0.915 ml 1.829 ml
    50 mM 0.037 ml 0.183 ml 0.366 ml
  • 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:


質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)


  • =
    *
    *


源葉所有產(chǎn)品僅用作科學(xué)研究,銷售產(chǎn)品行為均適用于我司網(wǎng)上所列通用銷售條款。